Provectus Biopharmaceuticals, Inc. is a development stage biopharmaceutical company that is primarily engaged in developing ethical pharmaceuticals for oncology and dermatology indications. The Company focuses on developing its prescription drug candidates PV-10 and PH-10. Provectus is developing PV-10 for treatment of several life threatening cancers including metastatic melanoma, liver cancer, and breast cancer. The Company is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions such as psoriasis and atopic dermatitis, a type of eczema.